| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13122 R50019 |
Marks (Controls exposed to Bupropion), 2021 | Any adaptation syndrome (Neonatal abstinence syndrome (NAS) or Pediatric adaptation syndromes (PAS)) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
2.26 [1.30;3.95] excluded (control group) |
51/581 19/406 | 70 | 581 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13123 R50030 |
Marks (Controls unexposed, sick), 2021 | Any adaptation syndrome (Neonatal abstinence syndrome (NAS) or Pediatric adaptation syndromes (PAS)) | 3rd trimester | retrospective cohort | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 4.20 [2.76;6.38] | -/283 -/- | - | 283 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8155 R25122 |
Dave, 2019 | Neonatal abstinence syndrome | 3rd trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 8.22 [5.62;12.02] C | 28/3,365 631/618,575 | 659 | 3,365 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 5.91 [3.06;11.41] | 659 | 3,648 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 13122